Skip to main content

Advertisement

SpringerLink
Log in

Lipids and diabetic nephropathy

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Although several factors may mediate the development and progression of diabetic nephropathy, hyperlipidemia is now considered an independent and major determinant of progression of renal disease in diabetes. The following discussion focuses on the experimental evidence that incriminates hyperlipidemia as a pathogenic factor for diabetic nephropathy and the potential mechanisms that may mediate renal injury from hyperlipidemia, as well as the clinical studies involving therapeutic interventions for hyperlipidemia and their impact on progression of diabetic renal disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Ayodele OE, Alebiosu CO, Salako BL: Diabetic nephropathy —a review of the natural history, burden, risk factors and treatment. J Natl Med Assoc 2004, 96:1445–1454.

    PubMed  Google Scholar 

  2. Parving HH, Mauer M, Ritz E: Diabetic nephropathy. In Brenner & Rector’s The Kidney, edn 7. Edited by Brenner BM. Philadelphia: WB Saunders; 2004:1777–1818.

    Google Scholar 

  3. Moorhead JF, El Nahas M, Chan MK, Varghese Z: Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982, 1:1309–1311.

    Article  Google Scholar 

  4. Krolewski AS, Warram JHG, Christlies AR: Hypercholesterolemia-A determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int Suppl 1994, 45:S125-S131.

    PubMed  CAS  Google Scholar 

  5. Ravid M, Neumann L, Lishner M: Plasma lipids and the progression of nephropathy in diabetes mellitus type 2: effect of ACE inhibitors. Kidney Int 1995, 47:907–910.

    Article  PubMed  CAS  Google Scholar 

  6. Gall MA, Hougaard P, Barch-Johnsen K, et al.: Risk factors for development of incipient and overt diabetic nephropathy in patients with noninsulin-dependent diabetes mellitus: prospective observational study. BMJ 1997, 314:783–788.

    PubMed  CAS  Google Scholar 

  7. Klein R, Klein BEK, Moss SE, et al.: The 10-year incidence of renal insufficiency in people with type-1 diabetes. Diabetes Care 1999, 22:743–751.

    Article  PubMed  CAS  Google Scholar 

  8. Bonnet F, Cooper ME: Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies. Diabetes Metab 2000, 26:254–264.

    PubMed  CAS  Google Scholar 

  9. Hirano T: Lipoprotein abnormalities in diabetic nephropathy. Kidney Int Suppl 1999, 71:S22-S24.

    Article  PubMed  CAS  Google Scholar 

  10. Chen HC, Guh JY, Chang JM, et al.: Role of lipid control in diabetic nephropathy. Kidney Int 2005, 67:S60-S62. The authors extensively review the role of lipid in mediating renal injury and the beneficial effects of lipid control in DN.

    Article  Google Scholar 

  11. Trovati M, Cavalot F: Optimization of hypolipidemic and antiplatelet treatment in the diabetic patient with renal disease. J Am Soc Nephrol 2004, 15:S12-S20.

    Article  PubMed  CAS  Google Scholar 

  12. Kahri J, Groop PH, Elliott T, et al.: Plasma cholesteryl ester transfer protein and its relationship to plasma lipoproteins and apolipoprotein A-I containing lipoproteins in IDDM patients with microalbuminuria and clinical nephropathy. Diabetes Care 1994, 17:412–419.

    Article  PubMed  CAS  Google Scholar 

  13. Groop PH, Elliott T, Ekstrand A, et al.: Multiple lipoprotein abnormalities in type I diabetic patients with renal disease. Diabetes 1996, 45:974–979.

    Article  PubMed  Google Scholar 

  14. Jensen T, Stender S, Deckert T: Abnormalities in plasma concentrations of lipoproteins and fibrinogen in type 1 (insulin-dependent) diabetic patients with increased urinary albumin excretion. Diabetologia 1988, 31:142–145.

    Article  PubMed  CAS  Google Scholar 

  15. Jerums G, Allen TJ, Tsalamandris C, et al.: Relationship of progressively increasing albuminuria to apoprotein[a] and blood pressure in type 2 (non insulin-dependent) and type 1 (insulin-dependent) diabetic patients. Diabetologia 1993, 36:1037–1044.

    Article  PubMed  CAS  Google Scholar 

  16. Kasiske BL, O’Donnell MP, Schmitz PG, et al.: The renal injury of diet-induced hypercholesterolemia in rats. Kidney Int 1990, 37:880–891.

    PubMed  CAS  Google Scholar 

  17. Misra Luthra K, Misra A, Srivastava LM: Lipoprotein (a): biology and role in atherosclerotic vascular disease. Curr Sci 1999, 76:1553–1560.

    Google Scholar 

  18. Grone HJ, Hohbach J, Grone EF: Modulation of glomerulosclerosis and interstitial fibrosis by native and modi.ed lipoprotein. Kidney Int Suppl 1996, 49:S18-S22.

    Google Scholar 

  19. Chander PN, Gealekman O, Brodsky SV, et al.: Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen. J Am Soc Nephrol 2004, 15:2391–2403.

    Article  PubMed  CAS  Google Scholar 

  20. Takemura T, Yoshioka K, Aya N, et al.: Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases. Kidney Int 1993, 43:918–927.

    PubMed  CAS  Google Scholar 

  21. Guijarro C, Kasiske BL, Kim Y, et al.: Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am J Kidney Dis, 1995, 26:152–161.

    PubMed  CAS  Google Scholar 

  22. Pesek-Diamond I, Ding G, Frye J, Diamond JR: Macrophages mediate adverse effects of cholesterol feeding in experimental nephrosis. Am J Physiol 1992, 263:F776-F783.

    PubMed  CAS  Google Scholar 

  23. Cooper ME, Jandeleit-Dahm KAM: Lipids and diabetic renal disease. Curr Diab Rep 2005, 5:445–448.

    Article  PubMed  CAS  Google Scholar 

  24. Remuzzi G, Ruggenenti P, Benigni A: Understanding the nature of renal disease progression. Kidney Int 1997, 51:2–15.

    Article  PubMed  CAS  Google Scholar 

  25. Schlondorff D: Cellular mechanisms of lipid injury in the glomerulus. Am J Kidney Dis 1993, 22:72–82.

    PubMed  CAS  Google Scholar 

  26. Krane V, Wanner C: At which stage of chronic kidney disease should dyslipidemia be treated? Nat Clin Pract Nephrol 2006, 2:176–177.

    Article  PubMed  Google Scholar 

  27. Keilani T, Schlueter W, Batlle D: Selected aspects of ACE inhibitor therapy for patients with renal disease: impact on proteinuria, lipids and potassium. J Clin Pharmacol 1995, 35:87–97.

    PubMed  CAS  Google Scholar 

  28. Mulec H, Johnsen SA, Wiklund O, Bjorck S: Cholesterol: a renal risk factor in diabetic nephropathy? Am J Kidney Dis 1993, 22:196–201.

    PubMed  CAS  Google Scholar 

  29. Wilson WF, Myers RH, Larson MG, et al.: Apolipoprotein E alleles, dyslipidemia and coronary artery disease: the Framingham offspring study. JAMA 1994, 272:1666–1671.

    Article  PubMed  CAS  Google Scholar 

  30. Chowdhury TA, Dyer PH, Kumar S, et al.: Association of apolipoprotein epsilon2 allele with diabetic nephropathy in Caucasian subjects with NIDDM. Diabetes 1998, 47:278–280.

    PubMed  CAS  Google Scholar 

  31. Werle E, Fiehn W, Hasslacher C: Apolipoprotein E polymorphism and renal function in German type 1 and type 2 diabetic patients. Diabetes Care 1998, 21:994–998.

    Article  PubMed  CAS  Google Scholar 

  32. Onuma T, Laffel LM, Angelico MC, Krolewski AS: Apolipoprotein E genotypes and risk of diabetic nephropathy. J Am Soc Nephrol 1996, 7:1075–1078.

    PubMed  CAS  Google Scholar 

  33. Hadjadj S, Gallois Y, Bouhanick B, et al.: Lack of contribution of lipid gene polymorphisms to IDDM nephropathy: the GENEDIAB Study [abstract]. Diabetologia 1998, 41(suppl 1):A293.

    Google Scholar 

  34. Eto M, Saito M, Okada M, et al.: Apolipoprotein e genetic polymorphism, remnant lipoproteins, and nephrology in type 2 diabetic patients. Am J Kidney Dis 2002, 40:243–251.

    Article  PubMed  CAS  Google Scholar 

  35. Kimura H, Suzuki Y, Gejyo F, et al.: Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM. Am J Kidney Dis 1998, 31:666–673.

    PubMed  CAS  Google Scholar 

  36. Boizel R, Benhamou PY, Corticelli P, et al.: Apo E polymorphism and albuminuria in diabetes mellitus: a role for LDL in the development of nephropathy in NIDDM? Nephrol Dial Transplant 1998, 13:72–75.

    Article  PubMed  CAS  Google Scholar 

  37. Forbes JM, Cooper ME, Old field MD, Thomas MC: Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol 2003, 14:S254-S258.

    Article  PubMed  CAS  Google Scholar 

  38. Lassila M, Seah KK, Allen TJ, et al.: Accelerated nephropathy in diabetic apolipoprotein E-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol 2004, 15:2125–2138.

    Article  PubMed  CAS  Google Scholar 

  39. McFarlane SI, Muniyappa R, Francisco R, Sowers JR: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 2002, 87:1457–1458.

    Article  Google Scholar 

  40. Athyros VG, Papageorgiou AA, Elisaf M, Mikhalidis DP: Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin 2003, 19:615–617.

    Article  PubMed  CAS  Google Scholar 

  41. Inman SR, Stowe NT, Cressman MD, et al.: Lovastatin preserves renal function in experimental diabetes. Am J Med Sci 1999, 317:215–221.

    Article  PubMed  CAS  Google Scholar 

  42. Kim SI, Han DC, Lee HB: Lovastatin inhibits transforming growth factor-beta 1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol 2000, 11:80–87.

    PubMed  CAS  Google Scholar 

  43. Jandeleit-Dahm K, Cao Z, Cox AJ, et al.: Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. Kidney Int Suppl 1999, 56:S31-S36.

    Article  Google Scholar 

  44. Lee SK, Jin SY, Han DC, et al.: Effects of delayed treatment with enalapril and/or lovastatin on the progression of glomerulosclerosis in 5/6 nephrectomized rats. Nephrol Dial Transplant 1993, 8:1338–1343.

    PubMed  CAS  Google Scholar 

  45. Park YS, Guijarro C, Kim Y, et al.: Lovastatin reduces glomerular macrophage in flux and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am J Kidney Dis 1998, 31:190 -194.

    PubMed  CAS  Google Scholar 

  46. Fried LF, Orchard TJ, Kasiske BL: The effect of lipid reduction on renal disease progression. A meta-analysis. Kidney Int 2001, 59:260–269.

    Article  PubMed  CAS  Google Scholar 

  47. Lam KSL, Cheng IKP, Janus ED, et al.: Cholesterollowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995, 38:604–609.

    PubMed  CAS  Google Scholar 

  48. Tonolo G, Calvia P, Ciccarese M, et al.: Reduction of albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int Suppl 1994, 45:S145-S149.

    Google Scholar 

  49. Smulders YM, van Eeden AE, Stehouwer CD, et al.: Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus? Eur J Clin Invest 1997, 27:997–1002.

    Article  PubMed  CAS  Google Scholar 

  50. Harris KPG, Wheeler DC, Chong CC: A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. The Atorvastatin in CAPD Study investigators. Kidney Int 2002, 61:1469–1474.

    Article  PubMed  CAS  Google Scholar 

  51. PDR Drug Interactions. In The PDR Electronic Library Version. Montvale, NJ: Thomson PDR; 2004:6.1.301A-304A.

  52. Weiner DE, Sarnak MJ: Managing dyslipidemia in chronic kidney disease. J Gen Intern Med 2004, 19:1045–1052.

    Article  PubMed  Google Scholar 

  53. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia. The Diabetes Atorvastatin Lipid Intervention (DALI) Study Group [no authors listed]. Diabetes Care 2001, 24:1335-1341.

  54. Wanner C, Krane V, Marz W, et al.: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238–248.

    Article  PubMed  CAS  Google Scholar 

  55. Owada A, Suda, S, Hata T: Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial. Am J Med 2003, 114:347–353.

    Article  PubMed  CAS  Google Scholar 

  56. Stewart KJ: Exercise training and the cardiovascular consequences of type-2 diabetes and hypertension. Plausible mechanisms for improving cardiovascular health. JAMA 2002, 288:1622–1631.

    Article  PubMed  Google Scholar 

  57. Nakamura T, Kawagoe Y, Ogawa H, et al.: Effect of low-density lipoprotein apheresis on urinary protein and podocyte excretion in patients with nephrotic syndrome due to diabetic nephropathy. Am J Kidney Dis 2005, 45:48–53. The authors describe a relatively new modality of therapy that in.uenced proteinuria and the progression of DN.

    Article  PubMed  Google Scholar 

  58. Haffner SM; American Diabetes Association: Management of dyslipidemia in adults with diabetes. Diabetes Care 2003, 26(suppl 1):S83-S86.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology Department of Medicine and Physiology, Texas Tech University Health Sciences Center, 3601, 4th Street, 4C-178, 79430, Lubbock, TX, USA

    Sharma Prabhakar MD, MBA

Authors
  1. Rey F. Rosario MPH, MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sharma Prabhakar MD, MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sharma Prabhakar MD, MBA.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosario, R.F., Prabhakar, S. Lipids and diabetic nephropathy. Curr Diab Rep 6, 455–462 (2006). https://doi.org/10.1007/s11892-006-0079-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-006-0079-7

Keywords

Search

Navigation